Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel versus docetaxel + lapatinib in recurrent or metastatic SCCHN
NL-OMON22962Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, lapatinib and pegfilgrastim in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical benefit at week 8. Started Mar 2009; status: recruiting.
02
Drugs
docetaxellapatinibpegfilgrastim
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON22962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22962.